Literature DB >> 30033872

Pleiotropic Effects of Statins: Untapped Potential for Statin Pharmacotherapy.

S Mohammad1, H Nguyen1,2, M Nguyen3, M Abdel-Rasoul4, V Nguyen5, C D Nguyen6, K T Nguyen6, L Li7, J P Kitzmiller1.   

Abstract

BACKGROUND: Statins are effective for primary and secondary prevention of atherosclerotic cardiovascular disease. They also have systemic anti-inflammatory and immunomodulating properties suggesting potential utility for improving clinical outcomes for a wide range of diseases. The literature provides data suggesting benefit in patients with comorbidities associated with contrast-induced nephropathy (CIN), chronic obstructive pulmonary disease (COPD), pneumonia, head injury, neurological disease (e.g. Alzheimer's and Parkinson's disease), prostate cancer, nuclear cataract and spinal cord injury. This systematic review evaluates the current evidence supporting the potential benefit of statins outside their customary role of attenuating cardiovascular risk reduction.
METHODS: The electronic databases MEDLINE, EMBASE, and clinicaltrials.gov were searched for studies published January 2000 - March 2018 reporting comorbidity reduction associated with statin use.
RESULTS: Fifty-eight publications that satisfied our selection criteria (based on the PRISM guidance for systematic reviews) were selected and included case-control, cohort, cross-sectional and observational studies as well as systematic reviews and meta-analyses. Ten studies addressed statin use and incidence of CIN after coronary imaging; 8 addressed statin use in patients with COPD; 14 addressed statin use and comorbidity reduction associated with head injury and/or a neurological disease disorder; 5 addressed the association between statin use and nuclear cataract; 9 addressed the association between statin use and prostate/colorectal cancer; 9 studies addressed the role of statin use in treating infections; and 3 addressed the association between statin use and spinal cord injury related survival rate.
CONCLUSION: Overall, the literature supports beneficial pleiotropic effects of statin use in contrastinduced nephropathy, head injury, Alzheimer's and Parkinson's disease, nuclear cataract, prostate cancer, infection management, and spinal cord injury. Further investigation is warranted, and randomized clinical trials are needed to confirm the clinical utility suggested by the reported studies included in this meta-analysis. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Alzheimer; Parkinson; Pleiotropic effects; acutezzm321990nephropathy; atherosclerotic cardiovascular disease; pharmacotherapy; stains.

Year:  2019        PMID: 30033872     DOI: 10.2174/1570161116666180723120608

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  19 in total

1.  Anti-atherosclerotic Effects of Myrtenal in High-Fat Diet-Induced Atherosclerosis in Rats.

Authors:  Liyan Yu; Hongguang Liu; Xiaoxia Ma; Vidya Devanathadesikan Seshadri; Xuan Gao
Journal:  Appl Biochem Biotechnol       Date:  2022-07-09       Impact factor: 2.926

Review 2.  Pharmacogenomics of statins: lipid response and other outcomes in Brazilian cohorts.

Authors:  Carolina Dagli-Hernandez; Yitian Zhou; Volker Martin Lauschke; Fabiana Dalla Vecchia Genvigir; Thiago Dominguez Crespo Hirata; Mario Hiroyuki Hirata; Rosario Dominguez Crespo Hirata
Journal:  Pharmacol Rep       Date:  2021-08-17       Impact factor: 3.024

3.  Simvastatin Induces Delayed Apoptosis Through Disruption of Glycolysis and Mitochondrial Impairment in Neuroblastoma Cells.

Authors:  Crystal L Kuzyk; Colin C Anderson; James R Roede
Journal:  Clin Transl Sci       Date:  2020-02-06       Impact factor: 4.689

4.  Association between Statin Use and Sepsis Risk in Patients with Dementia: A Retrospective Cohort Study.

Authors:  Liang-Tsai Yeh; Chuan-Yi Tang; Shun-Fa Yang; Han-Wei Yeh; Ying-Tung Yeh; Yu-Hsun Wang; Ming-Chih Chou; Chao-Bin Yeh; Chi-Ho Chan
Journal:  Int J Environ Res Public Health       Date:  2019-05-09       Impact factor: 3.390

5.  Effect of statins on lipid metabolism-related microRNA expression in HepG2 cells.

Authors:  Alvaro Cerda; Raul Hernandes Bortolin; Victor Manriquez; Luis Salazar; Tomas Zambrano; Cristina Moreno Fajardo; Mario Hiroyuki Hirata; Rosario Dominguez Crespo Hirata
Journal:  Pharmacol Rep       Date:  2021-03-15       Impact factor: 3.024

6.  Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic.

Authors:  Niki Katsiki; Maciej Banach; Dimitri P Mikhailidis
Journal:  Arch Med Sci       Date:  2020-04-14       Impact factor: 3.318

Review 7.  Treating Influenza Infection, From Now and Into the Future.

Authors:  Sophia Davidson
Journal:  Front Immunol       Date:  2018-09-10       Impact factor: 7.561

8.  [18F]Atorvastatin: synthesis of a potential molecular imaging tool for the assessment of statin-related mechanisms of action.

Authors:  Gonçalo S Clemente; Jens Rickmeier; Inês F Antunes; Tryfon Zarganes-Tzitzikas; Alexander Dömling; Tobias Ritter; Philip H Elsinga
Journal:  EJNMMI Res       Date:  2020-04-15       Impact factor: 3.138

9.  Cholesterol reducer and thrombolytic therapy in acute ischemic stroke patients.

Authors:  Nicolas Poupore; Dan Strat; Tristan Mackey; Katherine Brown; Ashley Snell; Thomas I Nathaniel
Journal:  Lipids Health Dis       Date:  2020-05-06       Impact factor: 3.876

10.  Late-Stage Copper-Catalyzed Radiofluorination of an Arylboronic Ester Derivative of Atorvastatin.

Authors:  Gonçalo S Clemente; Tryfon Zarganes-Tzitzikas; Alexander Dömling; Philip H Elsinga
Journal:  Molecules       Date:  2019-11-20       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.